Literature DB >> 27895297

Power of an Adaptive Trial Design for Endovascular Stroke Studies: Simulations Using IMS (Interventional Management of Stroke) III Data.

Maarten G Lansberg1, Ninad S Bhat2, Sharon D Yeatts2, Yuko Y Palesch2, Joseph P Broderick2, Gregory W Albers2, Tze L Lai2, Philip W Lavori2.   

Abstract

BACKGROUND AND
PURPOSE: Adaptive trial designs that allow enrichment of the study population through subgroup selection can increase the chance of a positive trial when there is a differential treatment effect among patient subgroups. The goal of this study is to illustrate the potential benefit of adaptive subgroup selection in endovascular stroke studies.
METHODS: We simulated the performance of a trial design with adaptive subgroup selection and compared it with that of a traditional design. Outcome data were based on 90-day modified Rankin Scale scores, observed in IMS III (Interventional Management of Stroke III), among patients with a vessel occlusion on baseline computed tomographic angiography (n=382). Patients were categorized based on 2 methods: (1) according to location of the arterial occlusive lesion and onset-to-randomization time and (2) according to onset-to-randomization time alone. The power to demonstrate a treatment benefit was based on 10 000 trial simulations for each design.
RESULTS: The treatment effect was relatively homogeneous across categories when patients were categorized based on arterial occlusive lesion and time. Consequently, the adaptive design had similar power (47%) compared with the fixed trial design (45%). There was a differential treatment effect when patients were categorized based on time alone, resulting in greater power with the adaptive design (82%) than with the fixed design (57%).
CONCLUSIONS: These simulations, based on real-world patient data, indicate that adaptive subgroup selection has merit in endovascular stroke trials as it substantially increases power when the treatment effect differs among subgroups in a predicted pattern.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  adaptive trial design; endovascular techniques; stroke

Mesh:

Year:  2016        PMID: 27895297      PMCID: PMC5134921          DOI: 10.1161/STROKEAHA.116.015436

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  16 in total

1.  Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group.

Authors:  Paul Gallo; Christy Chuang-Stein; Vladimir Dragalin; Brenda Gaydos; Michael Krams; José Pinheiro
Journal:  J Biopharm Stat       Date:  2006-05       Impact factor: 1.051

2.  Adaptive design of confirmatory trials: Advances and challenges.

Authors:  Tze Leung Lai; Philip W Lavori; Ka Wai Tsang
Journal:  Contemp Clin Trials       Date:  2015-06-14       Impact factor: 2.226

3.  Comparison of the response to endovascular reperfusion in relation to site of arterial occlusion.

Authors:  Robin Lemmens; Michael Mlynash; Matus Straka; Stephanie Kemp; Roland Bammer; Michael P Marks; Gregory W Albers; Maarten G Lansberg
Journal:  Neurology       Date:  2013-07-12       Impact factor: 9.910

4.  Differential Effect of Baseline Computed Tomographic Angiography Collaterals on Clinical Outcome in Patients Enrolled in the Interventional Management of Stroke III Trial.

Authors:  Bijoy K Menon; Emmad Qazi; Vivek Nambiar; Lydia D Foster; Sharon D Yeatts; David Liebeskind; Tudor G Jovin; Mayank Goyal; Michael D Hill; Thomas A Tomsick; Joseph P Broderick; Andrew M Demchuk
Journal:  Stroke       Date:  2015-03-19       Impact factor: 7.914

5.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

Authors:  Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

6.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

7.  Endovascular therapy after intravenous t-PA versus t-PA alone for stroke.

Authors:  Joseph P Broderick; Yuko Y Palesch; Andrew M Demchuk; Sharon D Yeatts; Pooja Khatri; Michael D Hill; Edward C Jauch; Tudor G Jovin; Bernard Yan; Frank L Silver; Rüdiger von Kummer; Carlos A Molina; Bart M Demaerschalk; Ronald Budzik; Wayne M Clark; Osama O Zaidat; Tim W Malisch; Mayank Goyal; Wouter J Schonewille; Mikael Mazighi; Stefan T Engelter; Craig Anderson; Judith Spilker; Janice Carrozzella; Karla J Ryckborst; L Scott Janis; Renée H Martin; Lydia D Foster; Thomas A Tomsick
Journal:  N Engl J Med       Date:  2013-02-07       Impact factor: 91.245

8.  Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the Interventional Management of Stroke III trial.

Authors:  Andrew M Demchuk; Mayank Goyal; Sharon D Yeatts; Janice Carrozzella; Lydia D Foster; Emmad Qazi; Michael D Hill; Tudor G Jovin; Marc Ribo; Bernard Yan; Osama O Zaidat; Donald Frei; Rüdiger von Kummer; Kevin M Cockroft; Pooja Khatri; David S Liebeskind; Thomas A Tomsick; Yuko Y Palesch; Joseph P Broderick
Journal:  Radiology       Date:  2014-06-05       Impact factor: 11.105

9.  Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

Authors:  Walter N Kernan; Catherine M Viscoli; Karen L Furie; Lawrence H Young; Silvio E Inzucchi; Mark Gorman; Peter D Guarino; Anne M Lovejoy; Peter N Peduzzi; Robin Conwit; Lawrence M Brass; Gregory G Schwartz; Harold P Adams; Leo Berger; Antonio Carolei; Wayne Clark; Bruce Coull; Gary A Ford; Dawn Kleindorfer; John R O'Leary; Mark W Parsons; Peter Ringleb; Souvik Sen; J David Spence; David Tanne; David Wang; Toni R Winder
Journal:  N Engl J Med       Date:  2016-02-17       Impact factor: 91.245

10.  Adaptive choice of patient subgroup for comparing two treatments.

Authors:  Tze Leung Lai; Philip W Lavori; Olivia Yueh-Wen Liao
Journal:  Contemp Clin Trials       Date:  2014-09-07       Impact factor: 2.226

View more
  1 in total

1.  Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist-a pragmatic tool to accelerate development of cell therapy products.

Authors:  Anjali Nagpal; Austin G Milton; Simon A Koblar; M Anne Hamilton-Bruce
Journal:  Stem Cell Res Ther       Date:  2021-01-29       Impact factor: 6.832

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.